XNAS · EYPT
-1.32% · -$0.0700 · Vol Not reported
Pre-market · updated 06:02:17 ET
EyePoint, Inc. Common Stock

EyePoint, Inc. Common Stock

LABORATORY ANALYTICAL INSTRUMENTS
$5.25
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
EYPT
EyePoint, Inc. Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

25/ 100
Veridion Score
AVOID · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is EYPT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading EYPT catalysts
About EyePoint, Inc. Common Stock
LABORATORY ANALYTICAL INSTRUMENTS
Listed since
2005
Employees
214
Country
US

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$5.32
Last session
Day high
$5.32
Last session
Day low
$5.32
Last session
Previous close
$5.32
52W high
$18.85
-72.15% from high
52W low
$4.87
3% of range
Market cap
$458.6M
EPS
$-3.7800
Beta
1.72
Shares out
86.2M
Avg volume
4.5M
VWAP
$5.32
Last session
Price history computed in-house
1W
+7.80%
1M
-56.93%
3M
-60.67%
1Y
-55.62%
YTD
-71.26%
SMA 50 $12.51 · below
SMA 200 $13.98 · below
52W position 3%

EYPT overview

Veridion Score
25
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around EYPT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading EYPT Form 4 filings
Public disclosures

Congress activity in EYPT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for EYPT in the cached public ledger.

Federal contracts

EYPT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EYPT in this window.
Lobbying spend

EYPT lobbying filings, year to date.

Registered lobbying filings matched to EyePoint, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EYPT in this window.
Loading news for EYPT
Analyst ratings
Sovereign unlock shows live analyst consensus for EYPT.
Options
Sovereign unlock shows live options positioning for EYPT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.